

SUPPLEMENTAL MATERIAL

Table S1. Sensitivity analyses on discontinuation of VKA treatment and the risk of stroke/TIA, by time since incident AF - (a) using 60-day grace period instead of 30-day grace period, (b) excluding AF patients with previous stroke/TIA, (c) restricting analysis to subset with AF onset after Jan 2008, (d) excluding AF patients with stroke/TIA within 60 days after AF and (e) subset with ischemic strokes only.

	Cases n (%)	Controls n (%)	Crude RR (95%-CI)	Adjusted RR (95%-CI)	Excess IR per 100 PY (95%-CI)
a. Grace period of 60 days					
Total	581	2625			
Current VKA use	370 (63.68)	2133 (81.26)	1	1	0
VKA discontinued	211 (36.32)	492 (18.74)	2.77 (2.23 - 3.46)	2.73 (2.18 - 3.41)	1.71 (1.15 to 2.28)
VKA discontinued ≤ 365 days	94 (16.18)	184 (7.01)	3.19 (2.37 - 4.29)	3.11 (2.30 - 4.22)	2.27 (1.33 to 3.20)
VKA discontinued ≤120 days	49 (8.43)	95 (3.62)	3.17 (2.16 - 4.66)	3.21 (2.17 - 4.74)	2.72 (1.05 to 4.39)
VKA discontinued >120 to ≤365 days	45 (7.75)	89 (3.39)	3.20 (2.13 - 4.82)	3.01 (1.99 - 4.56)	2.01 (0.63 to 3.39)
VKA discontinued >365 days	117 (20.14)	308 (11.73)	2.46 (1.86 - 3.26)	2.42 (1.82 - 3.23)	1.18 (0.70 to 1.66)
b. Excluding patients with history of stroke/TIA					
Total	365	1531			
Current VKA use	207 (56.71)	1194 (77.99)	1	1	0
VKA discontinued	158 (43.29)	337 (22.01)	3.01 (2.29 - 3.96)	3.00 (2.27 - 3.97)	1.66 (1.06 to 2.26)
VKA discontinued ≤ 365 days	64 (17.53)	131 (8.56)	3.03 (2.09 - 4.39)	2.96 (2.03 - 4.31)	1.75 (0.83 to 2.67)
VKA discontinued ≤120 days	33 (9.04)	62 (4.05)	3.05 (1.89 - 4.93)	2.99 (1.84 - 4.86)	1.76 (0.24 to 3.27)
VKA discontinued >120 to ≤365 days	31 (8.49)	69 (4.51)	3.00 (1.81 - 4.97)	2.92 (1.74 - 4.89)	1.47 (0.10 to 2.84)
VKA discontinued >365 days	94 (25.75)	206 (13.46)	2.99 (2.09 - 4.27)	3.05 (2.12 - 4.38)	1.43 (0.86 to 1.99)
c. AF onset after Jan 2008					
Total	204	921			
Current VKA use	141 (69.12)	770 (83.60)	1	1	0
VKA discontinued	63 (30.88)	151 (16.40)	2.52 (1.71 - 3.71)	2.45 (1.63 - 3.67)	1.79 (0.56 to 3.01)
VKA discontinued ≤ 365 days	39 (19.12)	83 (9.01)	2.78 (1.75 - 4.43)	2.62 (1.61 - 4.25)	2.04 (0.56 to 3.52)
VKA discontinued ≤120 days	20 (9.80)	45 (4.89)	2.55 (1.41 - 4.62)	2.51 (1.34 - 4.70)	2.05 (-0.65 to 4.75)
VKA discontinued >120 to ≤365 days	19 (9.31)	38 (4.13)	3.09 (1.64 - 5.82)	2.74 (1.42 - 5.27)	2.22 (-0.84 to 5.28)
VKA discontinued >365 days	24 (11.76)	68 (7.38)	2.16 (1.20 - 3.86)	2.20 (1.20 - 4.03)	0.97 (-0.05 to 1.99)
d. Excluding stroke/TIA in first 60 days after AF					
Total	405	1726			
Current VKA use	221 (54.57)	1286 (74.51)	1	1	0
VKA discontinued	184 (45.43)	440 (25.49)	2.48 (1.95 - 3.16)	2.57 (2.00 - 3.29)	1.49 (0.99 to 1.98)

	Cases n (%)	Controls n (%)	Crude RR (95%-CI)	Adjusted RR (95%-CI)	Excess IR per 100 PY (95%-CI)
VKA discontinued ≤ 365 days	80 (19.75)	181 (10.49)	2.54 (1.85 - 3.49)	2.60 (1.88 - 3.60)	1.66 (0.82 to 2.50)
VKA discontinued ≤120 days	40 (9.88)	95 (5.50)	2.29 (1.51 - 3.47)	2.44 (1.59 - 3.72)	1.75 (0.17 to 3.33)
VKA discontinued >120 to ≤365 days	40 (9.88)	86 (4.98)	2.86 (1.85 - 4.43)	2.80 (1.79 - 4.39)	1.87 (0.50 to 3.23)
VKA discontinued >365 days	104 (25.68)	259 (15.01)	2.44 (1.78 - 3.35)	2.54 (1.83 - 3.53)	1.34 (0.77 to 1.92)
e. Ischemic stroke					
Total	287	1245			
Current VKA use	157 (54.70)	975 (78.31)	1	1	0
VKA discontinued	130 (45.30)	270 (21.69)	3.08 (2.29 - 4.16)	3.11 (2.28 - 4.24)	1.19 (0.75 to 1.63)
VKA discontinued ≤365 days	60 (20.91)	112 (9.00)	3.40 (2.29 - 5.04)	3.31 (2.21 - 4.96)	1.41 (0.65 to 2.17)
VKA discontinued ≤120 days	30 (10.45)	55 (4.42)	3.08 (1.86 - 5.10)	2.79 (1.66 - 4.70)	1.24 (0.03 to 2.45)
VKA discontinued >120 to ≤365 days	30 (10.45)	57 (4.58)	3.87 (2.19 - 6.86)	4.14 (2.30 - 7.43)	1.86 (0.39 to 3.34)
VKA discontinued >365 days	70 (24.39)	158 (12.69)	2.81 (1.90 - 4.17)	2.94 (1.95 - 4.43)	0.95 (0.51 to 1.39)

AF: Atrial fibrillation; CI: Confidence interval; IR: Incidence rate; RR: Relative risk; PY: Person-years; TIA: Transient ischemic attack; VKA: Vitamin-K antagonist.

*: RR adjusted for smoking, body mass index, presentation of AF (i.e. ambulatory, primary hospital discharge, and non-primary hospital discharge diagnosis), and all CHA₂DS₂-VASc score components except for age and gender.